Contribution: Industrial Research Assistance Program – Contributions to Firms
Entos Pharmaceuticals Inc.
$10,000,000.00
COVID-19 Vaccine: Phase 3 Clinical Trial of DNA-Based Vaccine Booster Covigenix VAX-001-1c
EF 2022-23 · 2022-09-01
Résumé
Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001-1c bivalent vaccine candidate through Phase 3 clinical trials to establish its safety and immunogenicity in healthy adults as a booster to approved vaccines.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Edmonton|Edmonton, Alberta, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
816561112
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Modifications
Chaque version de l'entente telle que publiée, de la plus ancienne à la plus récente, avec son total à cette version. Le montant ci-dessus est le plus récent.
| Modification | Date | Exercice financier | Total |
|---|---|---|---|
| 0 | 2022-09-01 | 2022-23 | $10,000,000.00 |
| 1 | 2022-09-01 | 2022-23 | $10,000,000.00 |
Tel que publié
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 91 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 91 jours.
Agreement End Date
2024-03-31
Agreement Number
1000363
Agreement Start Date
2022-09-01
Agreement Title
COVID-19 Vaccine: Phase 3 Clinical Trial of DNA-Based Vaccine Booster Covigenix VAX-001-1c
Agreement Title (French)
Vaccin COVID-19 : Essai clinique de phase 3 du vaccin bivalent à base d’ADN VAX-001-1c de Covigenix.
Agreement Type
Contribution
Agreement Value
$10,000,000.00
Amendment Date
2023-12-04
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001-1c bivalent vaccine candidate through Phase 3 clinical trials to establish its safety and immunogenicity in healthy adults as a booster to approved vaccines.
Description (French)
Entos a développé le VAX-001 de Covigenix, un vaccin ADN à véhicule protéo-lipidique (PLV) destiné à la prévention de l’infection de la COVID-19 par le SRAS-CoV-2. Dans le cadre de ce projet, Entos fera progresser le candidat-vaccin bivalent VAX-001-1c jusqu’aux essais cliniques de phase 3 afin d’établir son innocuité et son immunogénicité chez les adultes en bonne santé, en tant que rappel des vaccins approuvés.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Edmonton Centre
Federal Riding (French)
Edmonton-Centre
Federal Riding Number
48014
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
816561112
Recipient City
Edmonton|Edmonton
Recipient Country
CA
Recipient Legal Name
Entos Pharmaceuticals Inc.
Recipient Postal Code
T5J 4P6
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2022-2023-Q4-1000363
